Yatharth Hospital & Trauma Care Services Limited is a prominent healthcare provider incorporated in February 2008 and converted into a public company on November 3, 2021. The company has emerged as one of North India's leading healthcare providers, known for its commitment to delivering high-quality medical care through a network of state-of-the-art facilities. The company operates an extensive network of hospitals across North India, providing comprehensive healthcare services ranging from primary care to advanced super-specialty treatments. Yatharth Hospital currently operates 7 hospitals across North India, with 87% of its beds located in Metro areas, making it a significant player in the Indian healthcare sector.
Yatharth Hospital's strategic presence spans across key locations in North India. The company operates facilities in:
- Greater Noida: 400 beds (112 ICU beds), 66% occupancy
- Noida: 250 beds (81 ICU beds), 83% occupancy
- Noida Extension: 450 beds (125 ICU beds), 60% occupancy (one of the largest hospitals in the region)
- Jhansi-Orchha: 305 beds (76 ICU beds), 47% occupancy (acquired Feb 2022)
- Greater Faridabad: 200 beds (61 ICU beds), 28% occupancy (operational since May 2024)
The company has been expanding its footprint strategically. In February 2022, it acquired a 305-bedded Ramraja Multi-Speciality Hospital in Orchha, Madhya Pradesh near Jhansi, Uttar Pradesh. In February 2024, it acquired a 200-bedded hospital in Faridabad, Haryana, which became operational in May 2024.
The company has ambitious growth plans with upcoming hospitals, including a facility in Model Town, Delhi (approximately 300 beds) and a new hospital in Faridabad (approximately 400 beds). During the quarter, the company received possession of two newly acquired hospitals in New Delhi and Faridabad, which are being operationalized in Q1 FY26. In 2024, Yatharth Hospitals launched its Radiation Oncology and Nuclear Medicine Center at the NOIDA Extension Facility, demonstrating its commitment to expanding specialized medical services.
Yatharth Hospital provides a wide spectrum of specialty services, including:
- Cardiology
- Neurosciences
- Pediatrics
- Gastroenterology
- Pulmonology
- Robotic Surgery
- Dermatology
- Endocrinology
- Dentistry
- Radiology
- Ophthalmology
- Cancer & Bone Marrow Transplant
- Nephrology & Urology
- General Surgery
- Psychology & Psychiatry
- Plastic & Cosmetic Surgery
- Vitro Fertilization (IVF) & Fertility
- Interventional Spine & Pain Medicine
- Nuclear Medicine
- Pathology & Laboratory Medicine
- Nutrition & Health
- Physiotherapy & Rehab
- Emergency Medicine
Yatharth Hospital & Trauma Care Services Ltd has a market capitalization of ₹5,962 crore as of July 2025, representing a significant increase of 45.5% over the past year. The company's financial performance has been robust, with revenue of ₹880 crore and profit of ₹131 crore for the latest financial year.
- Q1 FY25 Performance: Net profit rose 60% year-on-year to ₹30.4 crore, with revenue from operations increasing 37% to ₹211.8 crore.
- Q2 FY25 Performance: Net profit grew 12% year-on-year to ₹31 crore, with revenue from operations rising 27% to ₹217.8 crore.
- Q4 FY25 Performance: Revenue stood at ₹231.78 crore with a net profit of ₹38.72 crore as of March 2025.
- Operational Metrics: A 10% year-on-year rise in average revenue per occupied bed (ARPOB) to ₹30,597 in Q2 FY25, with bed occupancy improving to 60%.
- Market Capitalization: ₹5,962 crore (as of July 2025)
- Ajay Kumar Tyagi: Chairman and Whole-time Director, with a medical degree and over 16 years of experience in medical care and hospital management.
- Yatharth Tyagi: Whole-time Director, responsible for overall operations and business development.
- Ashutosh Kumar Jha: Group Chief for Strategy, M&A, and Investor Relations (appointed July 2025).
- Promoter Holding: 61.6% (decreased from 66.54% in June 2024 to 61.64% in March 2025).
- Initial Public Offer (IPO): July 2023, raised ₹686.56 crore (₹490 crore fresh issue, ₹196.56 crore offer for sale).
Yatharth Hospital & Trauma Care Services Ltd possesses several key strengths:
- Reduced Debt: The company has significantly reduced its debt and is almost debt-free, providing substantial financial flexibility for future expansion.
- Healthy Cash Flows: Reported healthy operating cash flows of ₹1,496 million in FY2025, with a cash conversion ratio of 68%, indicating strong profit to cash flow conversion.
- Strategic Location: Facilities are strategically located in high-demand metro areas.
- Focus on Super-Specialties: Emphasis on advanced and super-specialty services positions the company well to capitalize on India's growing healthcare needs.
- Growth Strategy: A balanced expansion strategy focusing on both organic growth (new facilities) and strategic acquisitions aims to strengthen its market position in North India's healthcare sector.
Yatharth Hospital represents a promising investment opportunity in India's expanding healthcare landscape, driven by its robust operational performance, strategic expansion, and strong management team.
